MaTOS GI Edition | Masters in Therapeutic Oncology Summit
Event Ended
This event has ended. Registration is no longer available.
Event Schedule
Event Overview
The 2026 Masters in Therapeutic Oncology Summit – Gastrointestinal Edition (MaTOS | GI Edition) is an advanced, CME-accredited forum designed to address identified practice gaps, share evolving clinical evidence, and elevate the standard of care for gastrointestinal cancers. Bringing together leading experts, investigators, and multidisciplinary care teams, the summit provides an immersive educational experience grounded in clinical science, interactive dialogue, and real-world applicability. Covering a broad spectrum of GI malignancies—including esophageal, gastric, hepatocellular, pancreatic, cholangiocarcinoma, colorectal, and rare tumors—the summit will focus on:
Evidence-based treatment approaches across disease stages
Precision oncology applications and biomarker-guided therapy
Innovations in surgical and radiation strategies
Integration of immunotherapy, targeted agents, and novel therapeutics
Use of MRD and liquid biopsy technologies in disease tracking
Management of special populations and rare presentations
Attendees will benefit from a dynamic mix of expert-led panels, moderated debates, roundtable case discussions, and keynote addresses. These sessions will provide practical guidance for complex clinical scenarios, illuminate future directions in GI oncology, and facilitate implementation of the latest diagnostic and therapeutic advances in day-to-day oncology practice.
MaTOS | GI Edition fosters a culture of multidisciplinary exchange and critical reflection. It will empower healthcare professionals to adopt novel approaches, improve clinical decision-making, and ultimately enhance patient-centered outcomes across the continuum of gastrointestinal cancer care.
Instructions for Credit
Thank you for attending this conference. Your feedback is valuable to us.
To receive your Certificate of Attendance, complete and submit the Evaluation Form. Once this form is submitted your certificate will be available for download.
Registered attendees can earn a maximum of 12.00 CME credits. You will be able to select the amount of credits being claimed.
Non-Physicians: Please select the ‘Other’ Certificate option on the dropdown to claim your certificate of attendance.
For questions regarding credit for this activity, please contact MEC at info@meccinc.com. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Credits
- AMA PRA Category 1 Credit™12.00
- Other (Physician)12.00
Event Details
- Duration
- 12.00 hours
- Start Date
- July 9th, 2026 1:00 PM (EDT)Central: July 9th, 2026 12:00 PMMountain: July 9th, 2026 11:00 AMPacific: July 9th, 2026 10:00 AM
- End Date
- July 12th, 2026 9:00 AM (EDT)Central: July 12th, 2026 8:00 AMMountain: July 12th, 2026 7:00 AMPacific: July 12th, 2026 6:00 AM
Objectives
Apply evolving standards of care in the treatment of GI cancers by integrating current evidence and expert consensus across diverse disease states including esophageal, gastric, pancreatic, hepatocellular, cholangiocarcinoma, and colorectal cancers.
Evaluate the role of surgery, radiation, and systemic therapy in curative, borderline, and advanced settings, with emphasis on case-based application and disease-specific considerations.
Incorporate molecular profiling and liquid biopsy techniques into diagnostic workflows, minimal residual disease (MRD) monitoring, and therapeutic decision-making.
Differentiate the clinical utility of immunotherapies and targeted therapies—including checkpoint inhibitors, FGFR inhibitors, HER2-targeted agents, and novel combinations—in early-stage and advanced GI malignancies.
Critically analyze real-world case discussions to develop personalized, evidence-based treatment plans for special patient populations, including those with comorbidities, germline mutations, or rare tumor types.
Discuss emerging therapies and future directions in GI oncology, including novel agents in development, tumor treating fields (TTFs), and precision treatment strategies projected for the next decade.
Interpret controversies and clinical trial evidence through moderated debates and expert panels, fostering nuanced understanding of differing approaches such as FLOT vs CROSS or the role of radiation in pancreatic and esophageal cancers.
Identify strategies to optimize multidisciplinary collaboration among oncologists, surgeons, radiologists, pathologists, and palliative care providers to enhance care delivery in complex GI oncology scenarios.
Target Audience
Physicians
Accreditation
In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Medical Educator Consortium designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.